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Bashir A. Lwaleeda, Mohamed O. Breishb, Brian R. Birchb,
Azeem P. Chowdharya, Rasheed A. Saadc, Oliver Perigob,
Rashid S. Kazmid, Luci M. Dussee and Alan J. CooperfPreeclampsia (P-EC) is a multisystem disorder of
pregnancy whose cause and pathogenesis remain poorly
understood. However, abnormal haemostasis and
endothelial dysfunction are thought to be implicated.
Women with a past medical history of P-EC have a baseline
hypercoagulable state postpregnancy. The aim of this study
is to examine the relationship between tissue factor (TF)
and TF pathway inhibitor (TFPI) in women who have had P-
EC within the last 3 years (more than 6 months postpartum)
and their normal counterparts. Blood specimens were
collected from women known to have had P-EC within the
last 3 years (nU26) and aged-matched healthy women
without past history of P-EC in previous pregnancy (nU26).
Plasma TF and TFPI levels were measured using ELISAs.
Women who have had P-EC showed increased TF levels
compared with their normal counterparts, whereas TFPI
levels were reduced. Neither parameter differed
significantly when the groups were tested against each
other. Interestingly, the TF/TFPI ratio was significantly
increased (PU0.024) when the two groups were compared.
In summary, there was a trend towards increased TF and
reduced TFPI levels in the P-EC group. Such a tendency was
not statistically significant. However, the TF/TFPI ratio was
significantly increased when the groups were compared.0957-5235  2014 Wolters Kluwer Health | Lippincott Williams & WilkinsOur findings suggest an imbalance between TF/TFPI levels
in womenwith past history of P-EC postpregnancy. Thismay
contribute to the development of maternal hypercoagulable
states and may predispose women with a history of P-EC to
cardiovascular risks later in life. Blood Coagul Fibrinolysis
25:000–000  2014 Wolters Kluwer Health | Lippincott
Williams & Wilkins.
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Tissue factor (TF) initiates blood coagulation by forming
a complex with circulating factor VII (FVII) and activated
FVII (FVIIa) [1]. This activity is regulated by TF path-
way inhibitor (TFPI) [2,3]. TF is important in pregnancy,
particularly in the first trimester, as it is required for
embryogenesis [4] as well as angiogenesis [5].
Normal pregnancy is associated with haemostatic
changes, tipping the balance towards hypercoagulability
[6]. This reverts back to prepregnancy levels 4–6 weeks
after delivery [7]. Preeclampsia (P-EC) is a major con-
tributor to perinatal morbidity and mortality. Approxi-
mately 5–7% of pregnancies are complicated by P-EC
[8], often necessitating premature delivery of the baby. It
is characterized clinically by high blood pressure and
proteinuria occurring after the 20th week of pregnancy
[9].
Several studies have demonstrated changes in haemo-
static parameters in women with P-EC [10–12].Recently, it has been highlighted that changes in the
maternal vasculature and coagulation profile may in turn
predispose women with P-EC to subsequent deleterious
cardiovascular consequences [13]. In this study, we
examine individual levels of and relationship between
TF and TFPI in women who have had P-EC compared
with normal counterparts.
Materials and methods
Participants
This was a case–control study comparing TF and TFPI
levels in a group of 26 women known to have had P-EC
between January 2008 and October 2011; a group of 26
healthy age-matched women who have not had P-EC
were also assessed (termed ‘control group hereafter’).
Ethical committee approval was granted for the study
by the Southampton and South West Hampshire
Research Ethics Committee. The participants were
asked to complete a general medical questionnaire to
confirm inclusion and exclusion criteria.DOI:10.1097/MBC.0000000000000120
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current pregnancy and women who had given birth less
than 6 months before testing. Comorbidities, including
chronic hypertension, obesity, presence of cardiovascular,
autoimmune/hepatic diseases, connective tissue dis-
orders, diabetes, coagulation disturbances and cancer,
women on anticoagulants or corticosteroids therapy were
also excluded from the study.
Sample size
A sample size calculation was performed, based on a 0.6
correlation coefficient between the TF, TFPI levels and
P-EC. The P value to assess this association was set to
5%, two-tailed. The power was 0.95. Given these criteria,
30 participants per arm would need to be recruited if the
drop-out rate reached 25%.
Specimen collection
A 5ml sample of venous blood was collected using a
21-gauge needle, into vacutainer tubes containing 3.8%
trisodium citrate. The bloods were then centrifuged at
3000 rpm for 10min at room temperature. Plasma
samples were then immediately isolated and transferred
into 250ml aliquots, which were then stored at 868C
until used for batch wise analysis. For each assay, a
previously unthawed aliquot was used.
Assays
Commercially available ELISA assays were used to
measure TF and TFPI (Quantikine Human coagulation
factor III/TF and TFPI; R&D Systems, UK). The intra-
assay and interassay coefficient of variations for the TF
and TFPI assays were 3.4 and 5.7%, and 3.6 and 5.9%,
respectively. Assays were performed according to the
manufacturers’ instructions.Table 1 Results of the general medical questionnaire completed by th
Women wi
Number of participants 26
Mean age of participants 33.6 ye
Minimum to maximum age 24–47
Mean BMI of participants 27.1
Family history of P-EC 6
Family history of hypertension 8
Family history of type II diabetes 4
Family history of myocardial infarction 5
Family history of deep vein thrombosis 1
Ethnic group 24 participants were w
1 white European; a
Current smokers 4
Regular exercise (moderate activity
for 30min at least 3 times a week)
5
Alcohol consumers 22 – average units co
3.3 units/week
Personal history of anaemia either during
or after pregnancy
3
Currently on contraception 6
P-EC, preeclampsia.Statistical analysis
Statistical analyses were performed using SPSS (Statisti-
cal Analysis System, Chicago, Illinois, USA, version 19 for
Windows). Data proved parametric, so summary statistics
were calculated as means and SD. However, the ratios are
not normally distributed, and thus expressed as a box and
whisker plot, with outliers additionally identified. Differ-
ences between ratios were assessed by Mann–Whitney
testing. The level for statistical significance was set at
P< 0.05. Assay results were recorded as ng/ml in original
sample.
Results
Demographic and clinical data
Characteristics of the groups are summarized in Table 1.
No significant difference was found in women’s age,
BMI, smoking status and alcohol consumption. However,
a number of women with P-EC had a family history of P-
EC (six out of 26) and hypertension (eight out of 26). The
control group was also sampled a year after last delivery.
Plasma tissue factor and plasma tissue factor pathway
inhibitor
Women with history of P-EC postpregnancy showed
slightly higher but statistically insignificant plasma TF
levels (0.075 0.01 ng/ml) when compared with the con-
trol group (0.056 0.007 ng/ml). Conversely, plasma
TFPI levels were slightly reduced in the P-EC group
(356 94.2 ng/ml) compared with controls (388 72.8 ng/
ml), but this was not significant.
Plasma tissue factor/tissue factor pathway inhibitor
ratio
The TF/TFPI ratio was significantly raised when women
with history of P-EC postpregnancy were compared with
controls (P¼ 0.024; Fig. 1).e study population
th P-EC Non-P-EC (controls)
26
ars 30.5 years
years 22–43 years
24.9
None
4
7
5
None
hite British;
nd 1 black African
22 participants were white British;
1 white European; 1 Mexican Latino;
1 black African; and 1 Indian
2
3
nsumed is 18 – average units consumed
is 3.2 units/week
None
9
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Fig. 1
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Plasma TF/TFPI ratio in the groups studied. Raw data were in ng/ml.
Results are shown as box and whisker plot (P¼0.024, Mann–Whitney).Discussion
P-EC is a complex multisystemic disorder and a main
cause of perinatal morbidity and mortality. There is
evidence suggesting that intravascular coagulation acti-
vation may be involved in the pathogenesis of P-EC [14].
Indeed, the process of intravascular coagulation acti-
vation may explain some of the clinical features associ-
ated with P-EC [15]. Coagulation indices may be of value
in monitoring P-EC progress [16]. Recent studies
suggested that a past history of P-EC may increase the
risk of cardiovascular disease later in life [13,17].
This study investigates the relationship between TF and
TFPI in women with a past history of P-EC and aged-
matched healthy women with no past history of P-EC.
The literature indicates that coagulation parameters nor-
malize within 2 months following birth [7]. In the present
study, both TF and TFPI measurements were made at
least 6 months postpartum. Almost all of our study
populations were in their 30s. Their family histories of
cardiovascular disease are detailed in Table 1. Cardio-
vascular disease and P-EC share many risk factors. In this
respect, the results that were particularly important were
the number of current smokers and women currently on
contraceptive medications. Although clinical and exper-
imental studies have documented that either active or
passive exposure to cigarette smoke promotes vasomotor
dysfunction and thrombosis in multiple vascular beds
[18], the analysis of plasma samples in those women
who smoked showed no significant change in TF and
TFPI levels. Likewise, women on contraception, includ-
ing oral, injection, transplant and intrauterine devices, (12
out of 40) showed no significant differences in TF and
TFPI levels. Thus, our findings are not in agreement
with studies linking the use of oral contraceptives to an
increased incidence of thrombovascular disease. It also
challenges a previous report with respect to increasedcoagulation factors VII, X and fibrinogen during oral
contraception usage [19].
During the course of pregnancy, preeclamptic women
showed significant increase in TF and TFPI levels
[12,20,21]. In the present study, we found no significant
difference in TF and TFPI levels in women who had
experienced P-EC within the last 3 years and their
normal counterparts, although the trend was towards
raised TF and reduced TFPI levels compared with
controls. Increasing cohort sizes may make the differ-
ences statistically significant, but not necessarily make
them any more practically important. However, when the
results were expressed as TF/TFPI ratio, we found a
significant increase in TF/TFPI ratio in women with a
past history of P-EC compared with controls (P¼ 0.024).
Our results showed no significant association between
plasma TF and plasma TFPI levels in the P-EC group.
This may be due to TFPI-1 being secreted by activated
or damaged vascular endothelial cells, including cells of
the microvasculature.
Several factors, such as hormonal or immune reaction,
could influence studies of coagulation proteins, which are
known to play an important role in the development of
P-EC [15,22]. Upon answering the questionnaire, women
were asked about medications in general without any
further stratification. Some particular medications,
such as oral contraceptive pills may affect the results.
Therefore, more selective criteria could enhance dis-
crimination. Clinically, P-EC is a very heterogeneous
condition with varying degrees of severity. We only
studied women who were diagnosed with P-EC gener-
ally, and these were not classified further. Correlating
results with severity of P-EC, further details about gesta-
tional age at delivery, baby weight, placental disease and
other pregnancy complications might add extra benefit to
future studies. The assays reported here were all based on
measurement of antigen; no functional tests were under-
taken. In the context of the antibodies involved, it also
meant that all of the target protein present was measured,
irrespective of complexity.
In summary, our study has examined the relationship
between plasma TF and TFPI in women who had P-EC
compared with their normal counterparts. The study
showed no significant changes in TF and TFPI levels.
However, the TF/TFPI ratio was significantly increased
in women with P-EC. The present result strongly sup-
ports the need for further work to examine the relation-
ship between plasma TF and TFPI postpartum levels. It
must be stated that this work should be seen as a pilot
study, which might add beneficial information to more
focused studies in the future.
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